Seamus Mulligan
Angel Investor
Atlanta, United States
Seamus Mulligan is a Series C investor in Atlanta focused on Medical and Health Care. Seamus Mulligan has served as a member of our Board of Directors since January 2012 and was our Chief Business Officer, International Business Development until February 2013. Since 2006, Seamus Mulligan has served as Executive Chairman of Circ Pharma Limited and its subsidiaries, a pharmaceutical development stage group. Prior to joining JazzPharmaceuticals in January 2012, he was the founder and principal investor of Azur Pharma, and served as Azur Pharma’s Chairman and Chief Executive Officer. Previously he held various positions with Elan Corporation, a pharmaceutical company, including managing the corporate development function, the drug delivery division, R&D and U.S. operations.Seamus Mulligan has worked in the pharmaceutical industry for over 25 years. He served as a member of the Board of Directors of the U.S. National Pharmaceutical Council until 2004.Seamus Mulligan holds a B.Sc. (Pharm) and M.Sc. from Trinity College, Dublin.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Seamus Mulligan invests in
Stages Seamus Mulligan invests in
Countries Seamus Mulligan invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (50%)
- Health Care 1 (50%)
- Biotechnology 1 (50%)
Stage
- Series C 1 (50%)
- Venture - Series Unknown 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Avectas
|
Avectas is a cell engineering technology company, enabling drug developers to manufacture potent engineered cell therapies at therapeutic volumes, with high efficiency and with minimal cell disruption. Avectas technology delivers advanced molecules such as mRNA, proteins and gene editing tools to a range of cell types including T cells forimmuno-oncology applications. Unlike the current industry standard of vector-free delivery methods, cells engineered with Avectas technology require no recovery time, leading to a shorter, simpler, more cost effective process. | $20M / Series C / Apr 16, 2020 | |
|
Avectas
|
Avectas is a cell engineering technology company, enabling drug developers to manufacture potent engineered cell therapies at therapeutic volumes, with high efficiency and with minimal cell disruption. Avectas technology delivers advanced molecules such as mRNA, proteins and gene editing tools to a range of cell types including T cells forimmuno-oncology applications. Unlike the current industry standard of vector-free delivery methods, cells engineered with Avectas technology require no recovery time, leading to a shorter, simpler, more cost effective process. | $10M / Venture - Series Unknown / Apr 08, 2019 |
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Seamus Mulligan invest in?
Seamus Mulligan invests primarily in Medical, Health Care and Biotechnology startups, most often at Series C and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Seamus Mulligan?
Public channels for Seamus Mulligan include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Seamus Mulligan last invest?
The most recent investment recorded for Seamus Mulligan closed in Apr 2020. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
